Hyperinsulinism-induced hypoglycemia secondary to asparaginase Erwinia chrysanthemi (recombinant)-rywn chemotherapy in a pediatric AML patient

Pediatr Blood Cancer. 2024 Apr;71(4):e30914. doi: 10.1002/pbc.30914. Epub 2024 Feb 6.

Authors

Ashley Carlo¹, Ally Watson², Genna Klein³, Steven Ghanny³, Shoshana Tell³, Tamar Horowitz¹, Molly Siver⁴, Burton Appel¹, Jing Chen¹

Affiliations

¹ Department of Pediatric Hematology/Oncology, Hackensack University Medical Center, Hackensack, New Jersey, USA.
² Department of Pediatrics, Hackensack University Medical Center, Hackensack, New Jersey, USA.
³ Department of Pediatric Endocrinology, Hackensack University Medical Center, Hackensack, New Jersey, USA.
⁴ Department of Pharmacy, Hackensack University Medical Center, Hackensack, New Jersey, USA.

PMID: 38321590
DOI: 10.1002/pbc.30914

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents* / therapeutic use
Asparaginase / adverse effects
Child
Dickeya chrysanthemi*
Erwinia*
Humans
Leukemia, Myeloid, Acute* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy

Substances

Asparaginase
Antineoplastic Agents